Sanofi, Multiple Sclerosis
Sanofi's Tolebrutinib Delays Disability Progression In Patients With Multiple Sclerosis, Data Shows
Sanofi reports positive phase 3 HERCULES study data for tolebrutinib in non-relapsing secondary progressive multiple sclerosis, showing a 31% delay in disability progression. Study also revealed increased disability improvement,
Women had a lower probability of receiving any disease-modifying treatment (DMT) and were even less likely to get ...
Sanofi has shared data from the phase 3 HERCULES trial that could rescue its multiple sclerosis (MS) drug candidate ...
A study presented at ECTRIMS 2024 has identified critical biomarkers that can predict disability worsening in multiple ...
Medpage Today on MSN4d
Higher Comorbidity Burden in Multiple Sclerosis Tied to Worse OutcomesHigher comorbidity burden among people with multiple sclerosis (MS) was associated with worse clinical outcomes, pooled trial ...
Vitamin D is linked to a 34% reduction in the relative risk for disease activity in patients with clinically isolated ...
High-dose cholecalciferol (vitamin D) is safe and can nearly double the time it takes for clinically isolated syndrome to ...
PHILADELPHIA.Today on MSN1d
Local Multiple Sclerosis Advocate Honored With State CitationBucks County resident Joseph “Smiley” Terinoni was recently presented with a citation from the Pennsylvania House of ...
Patients with MS showed half the rate of amyloid pathology compared with people without MS, suggesting a possible protective ...
Available disease-modifying therapies can prevent relapses and relapse-associated worsening in people with multiple sclerosis by targeting autoimmunity through various mechanisms. However, these ...
Among 282 patients with pediatric-onset MS, 39% started high-efficacy therapy early (at ages 12-17), and 61% started late ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback